OpenAI has just announced a new artificial intelligence model called GPT-Rosalind, marking a step forward in its ambition to expand the application of AI to life sciences, especially biological research and drug development.
GPT-Rosalind is named after Rosalind Franklin (a British scientist famous for her important contributions to the discovery of DNA structure). This model is designed to support fields such as biochemistry, drug detection and translocation medicine.
According to OpenAI, GPT-Rosalind has the ability to support scientists in many complex research stages, including document synthesis, hypothesis formulation, experimental planning and multi-step task processing.
Thanks to that, this tool can significantly shorten the early stages of the scientific discovery process.
In the context of increasing demand for AI applications in the pharmaceutical and biotechnology industries, the birth of GPT-Rosalind is expected to help research organizations and businesses accelerate the development of new drugs.
Users can access scientific databases, read the latest research works, and propose potential experimental directions.
Currently, GPT-Rosalind is provided as a research preview on platforms such as ChatGPT, Codex and OpenAI's API for qualified partners.
Along with that, the company also launched a free life science research plugin for Codex (an artificial intelligence system specializing in writing and programming support developed by OpenAI), connecting users with more than 50 tools and specialized data sources.
OpenAI said it has cooperated with many large enterprises in the pharmaceutical and biotechnology fields such as Amgen, Moderna and Thermo Fisher Scientific to deploy GPT-Rosalind into the practical research process.
This move takes place in the context of increasingly fierce AI competition. Previously, OpenAI also introduced a specialized model for network security, while competitor Anthropic launched its own advanced AI systems.
The development of GPT-Rosalind shows that the AI trend is not only stopping at chatbots or content creation, but is moving deeper into high-level specialized science fields.
If applied effectively, this technology can contribute to shortening research time, reducing costs and opening up breakthroughs in medicine.
